How Mebendazole overcomes Cancer Drug Resistance: 2025 Iran Paper
Cancer drug resistance significantly reduces the effectiveness of current anticancer treatments.
This highlights the need for developing new multi-targeting drugs that are more cost-effective, have fewer side effects, and remain effective against cancer. Drug repurposing offers a promising solution over expensive targeted therapies. Repurposing Mebendazole: it’s already been given to millions of people at high doses with a very good safety record, repurposing it for cancer is much faster and cheaper than inventing a brand-new drug. How MEBENDAZOLE Fights Cancer and Cancer Drug Resistance. This review breaks down six key ways Mebendazole attacks cancer. Mebendazole hits all of them at the same time, which is why it may overcome resistance better than single-target drugs: 1. Disrupts the cancer cell’s skeleton (microtubules) MBZ binds to the same spot on tubulin that the cancer drug colchicine uses. This stops cancer cells from properly dividing (they get stuck in the G2/M phase of the cell cycle and eventually die).It’s similar to some existing chemotherapies but appears safer. Starves the tumor of blood supply (anti-angiogenesis) 2. Tumors need new blood vessels to grow and get nutrients. MBZ blocks a key signal called VEGFR2, so the tumor can’t build those vessels. 3. Triggers programmed cell death (apoptosis) MBZ tips the balance of proteins inside the cell (raising “death-promoting” ones like Bax and p53, lowering “survival” ones like Bcl-2 and XIAP). This activates enzymes called caspases that make cancer cells commit suicide in an orderly way. 4. Forces cells to “eat” themselves (autophagy) Autophagy is the cell’s recycling system. MBZ can ramp it up so cancer cells digest their own damaged parts until they die or become easier to kill. 5. Mebendazole wakes up the immune system It shifts immune cells called macrophages from a “tumor-friendly” state (M2) to a “tumor-killing” state (M1 type). It also increases signals that attract other immune attackers and works especially well when combined with radiation. 6. Stops cancer from spreading (anti-metastasis and MMP inhibition) Cancer cells use enzymes called matrix metalloproteinases (MMPs) to chew through surrounding tissue and travel around the body. MBZ blocks them. Additionally, MBZ calms down several overactive growth pathways that cancers use to survive and resist drugs (examples: Hedgehog, ERK/MEK, MYC, NF-κB, AKT, etc.). What the evidence shows: Lab dishes (in vitro): Very low concentrations (often under 1–5 micromolar) kill or slow down breast, colon, lung, stomach, ovarian, melanoma, and brain cancer cells. MBZ works even better when paired with standard chemo or radiation. Mice (in vivo): Oral doses (10–50 mg/kg) shrink tumors, reduce the number of polyps in colon cancer models by up to 90 %, slow metastasis, and improve survival. Tumors weighed far less (e.g., one study: ~2 g vs. 12 g in untreated mice). Humans (early clinical trials): Small studies in brain tumors (Glioblastoma) and gastrointestinal cancers showed it is safe even at high doses (up to 4 g/day). One glioma trial reported median survival around 21 months when combined with standard treatment. The main practical challenge (and the fix). MBZ doesn’t dissolve well in water and isn’t absorbed very efficiently from the gut into the bloodstream or tumors. The review discusses new “drug delivery” solutions that researchers are testing:
This highlights the need for developing new multi-targeting drugs that are more cost-effective, have fewer side effects, and remain effective against cancer. Drug repurposing offers a promising solution over expensive targeted therapies. Repurposing Mebendazole: it’s already been given to millions of people at high doses with a very good safety record, repurposing it for cancer is much faster and cheaper than inventing a brand-new drug. How MEBENDAZOLE Fights Cancer and Cancer Drug Resistance. This review breaks down six key ways Mebendazole attacks cancer. Mebendazole hits all of them at the same time, which is why it may overcome resistance better than single-target drugs: 1. Disrupts the cancer cell’s skeleton (microtubules) MBZ binds to the same spot on tubulin that the cancer drug colchicine uses. This stops cancer cells from properly dividing (they get stuck in the G2/M phase of the cell cycle and eventually die).It’s similar to some existing chemotherapies but appears safer. Starves the tumor of blood supply (anti-angiogenesis) 2. Tumors need new blood vessels to grow and get nutrients. MBZ blocks a key signal called VEGFR2, so the tumor can’t build those vessels. 3. Triggers programmed cell death (apoptosis) MBZ tips the balance of proteins inside the cell (raising “death-promoting” ones like Bax and p53, lowering “survival” ones like Bcl-2 and XIAP). This activates enzymes called caspases that make cancer cells commit suicide in an orderly way. 4. Forces cells to “eat” themselves (autophagy) Autophagy is the cell’s recycling system. MBZ can ramp it up so cancer cells digest their own damaged parts until they die or become easier to kill. 5. Mebendazole wakes up the immune system It shifts immune cells called macrophages from a “tumor-friendly” state (M2) to a “tumor-killing” state (M1 type). It also increases signals that attract other immune attackers and works especially well when combined with radiation. 6. Stops cancer from spreading (anti-metastasis and MMP inhibition) Cancer cells use enzymes called matrix metalloproteinases (MMPs) to chew through surrounding tissue and travel around the body. MBZ blocks them. Additionally, MBZ calms down several overactive growth pathways that cancers use to survive and resist drugs (examples: Hedgehog, ERK/MEK, MYC, NF-κB, AKT, etc.). What the evidence shows: Lab dishes (in vitro): Very low concentrations (often under 1–5 micromolar) kill or slow down breast, colon, lung, stomach, ovarian, melanoma, and brain cancer cells. MBZ works even better when paired with standard chemo or radiation. Mice (in vivo): Oral doses (10–50 mg/kg) shrink tumors, reduce the number of polyps in colon cancer models by up to 90 %, slow metastasis, and improve survival. Tumors weighed far less (e.g., one study: ~2 g vs. 12 g in untreated mice). Humans (early clinical trials): Small studies in brain tumors (Glioblastoma) and gastrointestinal cancers showed it is safe even at high doses (up to 4 g/day). One glioma trial reported median survival around 21 months when combined with standard treatment. The main practical challenge (and the fix). MBZ doesn’t dissolve well in water and isn’t absorbed very efficiently from the gut into the bloodstream or tumors. The review discusses new “drug delivery” solutions that researchers are testing:
- polymeric nanoparticles
- nanostructured lipid carriers
- micelles
- nanosuspensions
Sources and References:
- Aliabadi et al - Critical dysregulated signaling pathways in drug resistance: highlighting the repositioning of mebendazole for cancer therapy. Front. Pharmacol. July 2025.
- William Makis. X.com (May 2026)
.png)
.png)
Comments
Post a Comment